Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
Can a targeted radiation drug delay prostate cancer progression without hormone therapy?
A phase 2 randomized controlled trial of 58 men with biochemically recurrent oligometastatic hormone-sensitive prostate cancer found Lu-PSMA…
A targeted radiation drug delayed prostate cancer progression by 20 months in early-stage patients without requiring hormone therapy first.
Synchronous bone-metastatic prostate cancer incidence 6% with median survival of 43 months in Chinese cohort
What happens when prostate cancer spreads to bones at diagnosis?
A retrospective cohort study of patients with synchronous bone-metastatic hormone-sensitive prostate cancer at a Chinese tertiary center fou…
About 6% of men diagnosed with prostate cancer already have it spread to their bones, where high-volume disease doubles the risk of death.